Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376163 | 0.98 | ALDH1A1 (0.39) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL16380580 | 0.87 | ADRB2 (0.40) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL28824160 | 0.87 | ADRB2 (0.40) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL23141734 | 0.86 | ALDH1A1 (0.41) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL29500422 | 0.86 | ALDH1A1 (0.41) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL15028294 | 0.86 | ALDH1A1 (0.41) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL6981492 | 0.85 | ADRB2 (0.41) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL14241236 | 0.84 | ALDH1A1 (0.42) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 | |
| SCHEMBL16376165 | 0.82 | ADRB2 (0.43) | ADRB2ADRB1ADRB3ALDH1A1MEN1 | |
| SCHEMBL28099782 | 0.81 | ALDH1A1 (0.46) | ADRB2ADRB1ADRB3ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | ADRB2 1626/4885ADRB1 922/4885ADRB3 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.